logo

For the Inventor, By the Inventor

Hamburg, Germany

Michael Paal

This inventor holds 17 USPTO granted patents, plus 2 CIPO patents and 1 EPO patent, primarily in Pharmaceutical Compounds. Top assignees: Eli Lilly and Company, Behringwerke Aktiengesellschaft, Beiersdorf-Lilly Gmbh. Active years: 1990-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Paal. Retrieved from https://idiyas.com/inventor/michael-paal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17

% Patents Active = 82.4



Average Co-Inventor Count = 6.5

ph-index = 8

Forward Citations = 215(Granted Patents)


Company Filing History:

goldMedal7 out of 4,517 
 
Eli Lilly and Company
 patents
silverMedal3 out of 340 
 
Behringwerke Aktiengesellschaft
 patents
bronzeMedal3 out of 4 
 
Beiersdorf-Lilly Gmbh
 patents
4. 1 out of 546 
 
Beiersdorf Ag
 patents
5. 3 out of 834,570 
Other
 patents

Years Active: 1990-2005

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Proliferative Diseases
Fibrinogen Inhibitors
Glycoprotein IIb/IIIa
Hypoglycemic Compounds
Protein Kinase C
Pyrimidine Compounds
Cardioactive Agents
Anthracycline Derivatives
Spiro Compounds
Cytostatic Activity
Pharmaceuticals
17 patents (USPTO):Explore Patents
1. 6867198 - Agents and methods for the treatment of proliferative diseases (2005-03-15),
2. 6693109 - Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation (2004-02-17),
3. 6528534 - Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation (2003-03-04),
4. 6448269 - Glycoprotein IIb/IIIa antagonists (2002-09-10),
5. 6410562 - Hypoglycemic imidazoline compounds (2002-06-25),
6. 6291469 - Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation (2001-09-18),
7. 6020362 - Glycoprotein IIB IIIA antagonists (2000-02-01),
8. 5731324 - Glycoprotein IIb/IIIa antagonists (1998-03-24),
9. 5672618 - Protein kinase C inhibitors (1997-09-30),
10. 5602137 - Pyrimidine compounds and their use as pharmaceuticals (1997-02-11),
11. 5602136 - Pyrimidine compounds and their use as pharmaceuticals (1997-02-11),
12. 5571813 - Fused pyrimidine compounds and their use as pharmaceuticals (1996-11-05),
13. 5545636 - Protein kinase C inhibitors (1996-08-13),
14. 5212186 - Cardioactive pyrrolobenzimidazoles (1993-05-18),
15. 4965352 - Anthracycline derivatives having cytostatic activity (1990-10-23),

Title: The Innovative Journey of Michael Paal

Introduction: Michael Paal, a visionary inventor hailing from Hamburg, Germany, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Michael Paal's latest patents include a cutting-edge software application for optimizing energy consumption in smart homes, a revolutionary medical device for non-invasive glucose monitoring, and a state-of-the-art drone technology for agricultural purposes.

Career Highlights: With over two decades of experience in the tech industry, Michael Paal has a proven track record of turning innovative ideas into reality. He has worked for renowned tech companies, leading research institutions, and universities, where he has spearheaded numerous projects that have pushed the boundaries of technology.

Collaborations: Throughout his career, Michael Paal has collaborated with top engineers, scientists, and researchers from around the world. His ability to work in multidisciplinary teams has led to the successful development of cutting-edge technologies that have had a lasting impact on various industries.

Conclusion: Michael Paal's passion for innovation, coupled with his technical expertise and collaborative spirit, has solidified his reputation as a pioneering inventor in the tech world. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…